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Abstract 
A  57-year-old  with  a  9-year  history  of
increased  abdominal  girth,  presented  with
increased abdominal pain, anemia, and acute
renal failure. His past medical history was only
remarkable for a previous lung cancer 21 years
ago that was treated with a right upper lung
lobectomy. A computed tomography (CT) scan
of  the  patient’s  abdomen  showed  a  solitary
20x20x25cm cystic splenic mass. The patient
underwent  an  urgent  splenectomy.  Intra-
operatively  a  large  splenic  cystic  cavity  was
found with a solid inferior splenic mass. An
exhaustive histological analysis of the splenic
mass confirmed a clear cell carcinoma with low
malignant potential that likely represented a
metastatic lesion from the patient’s previous
distant lung cancer. Postoperatively the patient
recovered  well  and  at  1-year  followup  the
patient demonstrated no further evidence of
metastatic  disease.  This  case  is  extremely
unique and provides a very rare example of a
metastatic solitary clear cell carcinoma to the
spleen, with a presumed latency period of more
than 20 years. 
Introduction
Clear cell carcinoma is a rare tumor cell type
that  differentiates  from  epithelial  cells  and
originates from various organs, including the
ovaries, endometrieum, kidneys, or lungs.1-4 It
is characterized by pale appearing cells that
are either fluid or glycogen filled, and in most
cases it is considered to be a malignant lesion.
Metastatic  clear  cells  to  the  spleen  are
extremely rare, with only one case of this pre-
viously reported in the English literature to the
best of our knowledge.5
Although the majority of splenic tumors are
discovered  incidentally  or  on  post-mortem
autopsies,6,7 they  can  uncommonly  illicit
abdominal pain, abnormal blood cell counts, or
acute  hemorrhagic  shock  resulting  from
splenic rupture.8 Notably, metastatic tumors to
the  spleen  are  rare,  and  solitary  metastatic
tumors are also exceedingly rare.9-12 We report
here a unique case of metastatic clear cell car-
cinoma to the spleen with a long latency peri-
od of over 20 years.
Case Report
A 57-year-old man with a distant history of a
right upper lobe clear cell carcinoma 21 years
ago developed an insidious slow-growing left
upper quadrant mass associated with intermit-
tent left upper quadrant pain over 9 years. In
August  2009,  after  two  weeks  of  frequent,
intermittent, severe, sharp left subcostal and
flank pain he sought out a Chinese herbalist.
He was provided with a ginseng-based remedy
and  was  urged  to  seek  further  professional
evaluation. 
He presented to medical attention approxi-
mately 1 month later in the hospital emergency
department.  He  was  hemodynamically  stable
but his physical examination was significant
for a large protuberant abdomen with moder-
ate-to-severe pain to palpation in the left upper
quadrant.  A  complete  blood  count  revealed
anemia  with  a  hematocrit  of  18.2%,  and  an
electrolyte panel revealed renal failure with a
serum creatinine of 3.3 mg/dL. A non-contrast
computed  tomography  (CT)  of  the  chest,
abdomen, and pelvis revealed a 20x20x25cm
cystic splenic mass (Figure 1). There was no
evidence of other primary or secondary tumors
outside  of  the  spleen.  The  right  upper  lung
lobe  was  not  present,  which  was  consistent
with the patient’s previous surgical history.
Upon admission the patient was transfused
with packed red blood cells and his hematocrit
responded appropriately. He remained hemo-
dynamically  stable.  Based  on  the  patient’s
symptoms and CT scan findings he was taken
urgently  to  the  operating  room  for  an
exploratory  laparotomy  and  a  splenectomy.
Intraoperatively,  a  very  large  encapsulated
spleen was encountered, and was removed in
its  entirety  (Figure  2A).  Variable  size  small
splenules  were  noted  in  the  peri-splenic  fat
pad, as well as attached to the gastro-splenic
ligament. The abdominal cavity was otherwise
normal with no other suspicious findings or
masses. There were no palpable lymph nodes. 
On  the  operating  room  back  table,  the
splenic mass was found to have a large cystic
cavity  that  contained  4  liters  of  brownish
serous fluid. A large stellate yellow mass meas-
uring 7.1x6.6x3.0cm was found attached to the
inferior inner wall of the splenic cystic cavity
(Figure 2B). The remaining wall of the splenic
cyst was thinned, and its inner surface was
covered with coarse trabeculae and adherent
fibrinous exudates (Figure 2B). Surrounding
the large cyst cavity was beefy red splenic tis-
sue,  measuring  3.9  cm  in  diameter  in  its
extension beyond the cyst.
Postoperatively the patient’s hospital course
was uncomplicated and he recovered well. His
creatinine level remained elevated at 3.1 mg/dL,
and a renal ultrasound during the patient’s hos-
pitalization  demonstrated  increased  bilateral
kidney echogenicity but no masses or hydro-
nephrosis. On postoperative day 5 the patient
was discharged from the hospital after receiv-
ing post-splenectomy vaccinations.
The  splenic  tissue  and  associated  mass
underwent an exhaustive histological analysis
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Figure  1.  Large  intra-peritoneal  splenic
mass. A representative cross-sectional axial
CT image demonstrates a large 20 x 20 cm
cystic splenic mass in the left upper quad-
rant of the abdomen. Compared to cystic
main body of the splenic mass, the inferio-
lateral border appears more solid. There is
associated mass effect with lateral displace-
ment of the mesentery and posterior dis-
placement of the left renal complex.[page 136] [Rare Tumors 2011; 3:e43]
(Table  1)  by  the  Veterans  Affairs  Palo  Alto
pathology department, and were also reviewed
by  colleagues  at  the  Stanford  University
Medical  Center,  and  the  Mayo  Clinic  at
Scottsdale. The specimen showed sheets and
clusters of cohesive cells with abundant clear
cytoplasm, mildly irregular nuclei and promi-
nent nucleoli (Figure 3A and 3B). Foci of clear
cells were found infiltrating surrounding nor-
mal splenic tissue as well as the lining of the
large cyst wall (Figure 3C and 3D). The find-
ings  were  most  consistent  with  a  low-grade
metastatic clear cell carcinoma with squamous
features.  Investigation  of  the  patient’s  past
medical records suggested that the splenic car-
cinoma  most  likely  resulted  from  a  delayed
metastasis from his prior lung carcinoma. 
On subsequent 6 month followup, positron
emission tomography (PET)-CT demonstrated
no scintigraphic evidence of malignancy, once
again confirming no other sites of disease. At
6-month  followup  the  patient’s  anemia  had
resolved, however his serum creatinine con-
tinued  to  be  elevated  from  baseline  with
nephritic  range  proteinuria  from  presumed
glomerulonephritis.  Microscopic  polyangitis
and membranous glomerulonephritis were the
leading diagnostic considerations for this, but
the patient declined a kidney biopsy to further
clarify  the  diagnosis.  At  1-year  followup  the
patient was clinically stable, with no further
evidence of malignancy.  
Discussion
Clear  cell  carcinoma  of  the  spleen  is  an
exceedingly rare entity, and to our knowledge
there is only one other reported case of this in
the literature.5 Metastatic tumors to the spleen
are  also  rare,  and  are  usually  undetected
except on post-mortem studies or in patients
with advanced or disseminated disease.6,7,13,14
We  report  here  a  patient  with  a  metastatic
clear cell carcinoma to the spleen. This case is
exceptionally unique in that the presumed pri-
mary site of the patient’s metastatic clear cell
carcinoma is from a prior lung cancer 21 years
prior, demonstrating an extraordinary latency
period that to our knowledge has never been
described for metastatic clear cell tumors.
More  commonly,  clear  cell  pathology  is
known to arise in ovarian, endometrial, and
renal  tumors.3-5,15 In  each  of  these  tissues,
clear cell tumors are typically associated with
aggressive metastatic behavior and poor clini-
cal outcomes. However, clear cell pathology of
other  tissue  types  has  been  described.
Pulmonary  clear  cell  carcinomas  are  a  rare
entity  that  are  described  in  a  few  case
reports.16-18 These tumors are not to be con-
fused  with  benign  pulmonary  sugar  cell
tumors,  which  also  have  a  large  clear  cyto-
plasm  but  are  distinguished  by  perivascular
epithelioid cell markers.19-21 Given the scarcity
of  reported  pulmonary  clear  cell  carcinoma
cases,  little  is  known  about  the  malignant
potential of these tumors and their prognosis.
Interestingly, the spleen is typically consid-
ered to be a hostile site for neoplastic implan-
tation, explaining the reported low incidence
of splenic metastatic lesions that are usually
encountered  and  reported  in  the  litera-
ture.6,16,22 This  phenomenon  is  partially
explained by the spleen’s reservoir for cellular
immunity, which may inherently infer signifi-
cant  anti-neoplastic  properties.  Anatomically,
the spleen also lacks afferent lymphatics, has a
tortuous splenic artery, and rhythmically con-
tracts. These features may decrease the likeli-
hood of neoplastic implantation to the splenic
parenchyma.22,23
Despite these protective features, metastat-
ic lesions to the spleen can occur and have
been rarely reported in several case series.6,10,14
Earlier series suggested that primary gynecol-
ogical tumors accounted for the majority of dis-
tant metastases to the spleen,10,24-27 but tumors
from other tissue such as the breast, colon,
Case Report
Figure 2. Postoperative gross appearance of the extracted splenic mass. A) Well encapsu-
lated splenic mass with associated overlying adventitial and adipose tissue. B) Opened
cystic cavity of splenic mass reveals an inner surface with course trabecule with fibrinous
exudates. A longitudinal section through the inferior pole splenic mass demonstrates a
pale appearing solid mass with surrounding red splenic tissue.
Table 1. Histological analysis.
Stain Purpose Findings Interpretation
PAS Glycogen deposits + Extensive glycogen in clear
cell cytoplasms
Trichome Collagen deposits + Collagenous bands infiltrating
islands of tumor cells
Congo red Amyloid proteins/deposits - No amyloid proteins
or deposits
Pankeratin Epithelial phenotype marker + Epithelial origin
Cytokeratin 7 Epithelial phenotype marker + Epithelial origin
S-100 Neural phenotype marker - Non-neurnal origin
Synaptophysin Neural or neuroendocrine  - Non-neurnal or
phenotype marker neuroendocrine origin
Chromogranin Neural or neuroendocrine  - Non-neurnal or
phenotype marker neuroendocrine origin
CD43 Lymphocytic marker - No lymphocytic lesions
CD3 Lymphocytic marker - No lymphocytic lesions
P63 Squamous differentiation marker + Clear cell squamous
differentiation
CD10 Renal clear cell carcinoma marker +/- Inconclusive
PAX2 Metastatic renal cell  - No evidence of renal cell
carcinoma marker carcinoma
HMB-45 Primary extra-pulmonary sugar  - No evidence of PEST
cell tumor (PEST) marker
Smooth muscle actin PEST marker - No evidence of PEST
Calretinin Methosthelioma marker - No methosthelioma
TTF-1 Adenocarcinoma marker - No adenocarcinoma
Ki-67 Mitotic activity - Very low mitotic activity[Rare Tumors 2011; 3:e43] [page 137]
and skin can also metastasis to the spleen at
lower rates.9,10,28 More recent studies suggest
that the majority of metastatic lesions to the
spleen arise from the lungs.29 In a summary of
713 clinical and post-mortem patient records,
21% of splenic metastasis were found to origi-
nate from primary lung tumors.6 The discrep-
ancy in metastatic lesions from primary tumor
sites likely reflects the differences in clinical
behavior and the treatment of different types
of advanced metastatic cancer over time, the
aggressiveness of the primary disease process,
as well as possible sampling error associated
with the examination of different study popu-
lations. Despite these differences, all studies
similarly conclude that distant metastasis to
the spleen occurs at a very low incidence rang-
ing  between  0.6-1.7%.6,10 Isolated  splenic
metastasis,  as  described  in  this  case,  is  an
even rarer finding with only approximately 50
reported cases of this in the literature.6,30-34
To confirm our pathological diagnosis ancil-
lary and immunohistochemical analysis of the
splenic  mass  specimen  was  vital  (Table  1).
Infiltrating clear cells within the inferior pole
splenic mass were found to avidly stain with PAS
(Figure 3C), which is consistent with extensive
glycogen deposits in the clear cell tumor cyto-
plasms.21,35 Furthermore, consistent with previ-
ous  reports,  clear  cells  were  found  to  be  of
epithelial origin (positive for Pankeratin, Figure
3D; and Cytokeratin 7), but negative for other
cell type markers.36,37 Markers for other metasta-
tic  lesions,  such  as  primary  extrapulmonary
sugar cell tumor (PEST), renal cell carcinoma
(RCC), and mesothelioma were also negative
(Table 1). Interestingly, Ki-67 staining demon-
strated low tumor mitotic activity, which is con-
sistent with the tumors presumed remarkably
long latency period and indolent slow growth.
In summary, we present an exceedingly rare
case of a solitary metastatic clear cell carcino-
ma to the spleen that likely originated from a
previous lung cancer more than 20 years earli-
er. The case provides insights about the malig-
nant  potential  of  clear  cell  carcionoma,  and
their potential metastatic sites, including the
spleen. For patients with solitary metastasis to
the spleen, splenectomy and continued surveil-
lance are excellent treatment options with a
potentially good outcome.
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